Cell mates: paracrine and stromal targets for prostate cancer therapy

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) historically had limited treatment options.
• Recent advances include systemic therapies improving survival, symptom control, and bone health.
• Current therapies primarily target malignant epithelial cells, overlooking tumor microenvironment interactions.

Purpose of the Study:

• To review current treatment landscape for mCRPC.
• To highlight the importance of understanding tumor microenvironment, including stromal and immune components.
• To identify novel therapeutic targets beyond malignant epithelial cells.

Main Methods:

• Review of recent advances in mCRPC treatment.
• Analysis of the role of androgen receptor signaling.
• Exploration of paracrine and stromal signals in tumor growth.
• Investigation of prostate cancer-immune system interactions.
• Consideration of epithelial-mesenchymal transition and circulating tumor cells.

Main Results:

• Multiple systemic therapies now offer significant benefits for mCRPC patients.
• Understanding mCRPC biology, especially androgen receptor signaling, has driven progress.
• Tumor stroma produces critical growth factors (VEGF, PDGF, FGF) and represents a therapeutic target.
• Prostate cancer-associated fibroblasts are a potential target.
• Immune system interactions, cytokines, chemokines, and growth factors are active research areas.
• Epithelial-mesenchymal transition and circulating tumor cells offer potential new targets.

Conclusions:

• Therapeutic strategies for mCRPC are expanding beyond targeting cancer cells alone.
• Targeting the tumor stroma, immune microenvironment, and cellular transition processes offers promising avenues for novel treatments.
• Further research into these complex interactions is crucial for developing more effective therapies for mCRPC.